This author's PDF version corresponds to the article as it appeared upon acceptance. Fully formatted PDF versions will be made available soon.

Efficacy of different interventions for nonalcoholic fatty liver disease: A meta-analysis of life style modifications, silymarin, and medications

doi: 10.6133/apjcn.202503/PP.0009 Published online: March 2025

Running title: Nonalcoholic fatty liver disease management

Zhen Zhang PhD¹, Shuai Li PhD¹, Jianjun Sun MD¹

¹Philippine Women's University, 1743 Taft Avenue, Malate, Manila 1004, Philippines.

Authors' email addresses and contributions:

ZZ: laverneterrill@gmail.com

Contribution: conceived the study question, and contributed to the study design, supervision of data collection, data analysis and interpretation, and editing the manuscript.

SL: laceylishuai@gmail.com

Contribution: undertook data collection and data analysis, and contributed to data interpretation, and writing the first draft of the manuscript.

JS: steven.jianjun@gmail.com

Contribution: undertook data collection and data analysis, and contributed to data interpretation, and writing the first draft of the manuscript.

Corresponding Author: Dr Zhen Zhang, Philippine Women's University, 1743 Taft Avenue, Malate, Manila 1004, Philippines. Tel: +86 18265952091. Email: laverneterrill@gmail.com.

ABSTRACT

Background and Objectives: To compare the effectiveness of silymarin or its combination with lifestyle modifications, Mediterranean hypocaloric diets, and medications for improving nonalcoholic fatty liver disease (NAFLD). Methods and Study Design: PubMed, Embase, Cochrane Library, Web of Science, and ClinicalTrails.gov were used to identify relevant studies. The treatment arm was silvmarin or its combination with Mediterranean hypocaloric diets, medications, or lifestyle modifications. The comparators were placebo, Mediterranean hypocaloric diets, medications, and lifestyle modifications. Results: This meta-analysis included 25 studies with 2283 patients. Total cholesterol levels were reduced by silymarin+Mediterranean hypocaloric diets (SMD: -0.39 (-0.81, 0.03), p=0.072) or medications [SMD: -1.12(-1.67, -0.58), p<0.001]. Triglyceride levels were decreased by silymarin combined with the medication [SMD: -0.92(-1.98, 0.14), p=0.080]. Low-density lipoprotein cholesterol levels were reduced by silymarin alone [SMD: -0.25(-0.48, -0.03), p=0.027]. The combination of silymarin with Mediterranean hypocaloric diets [SMD: -0.47(-0.90, -0.04), p=0.031] or lifestyle modifications [SMD: -0.88(-1.09, -0.66), p<0.0001] decreased alanine aminotransferase levels. Aspartate aminotransferase levels were reduced by a combination of silymarin and lifestyle modifications [SMD: -0.72(-1.49, 0.05), p=0.061] or medications [SMD: -1.41(-2.24, -0.59), p=0.005]. Silymarin (2.5 times) or silymarin plus lifestyle modifications (39%) reduced the hepatic steatosis rate in patients with NAFLD. The silymarin use increased the rate of patients with adverse effects [RR:1.98 (1.11, 3.54)]; gastrointestinal problems were the most common adverse effects. Conclusions: Despite the overall advantages of therapies, different interventions showed different effects on markers in patients with NAFLD. These results highlight the need for more research to fully comprehend the features of the intervention.

Key words: Lifestyle modification, silymarin, Nonalcoholic fatty liver disease, metaanalysis. Mediterranean hypocaloric diet.

INTRODUCTION

Nonalcoholic steatohepatitis (NASH) was first linked to excess liver fat in the absence of substantial alcohol consumption.¹ Then, the terms "nonalcoholic fatty liver disease (NAFLD)" and "metabolic associated fatty liver disease (MAFLD)" were developed to more accurately describe the disease process.^{2,3} The term MAFLD considers metabolic dysregulatory variables^{3,4}, such as type 2 diabetes mellitus (T2DM), overweight/obesity, and elevated body mass index (BMI), that may be varied in relation to ethnic groups [BMI \geq 25 kg/m² in Caucasians or BMI \geq 23 kg/m² in Asians)].⁴

Nonalcoholic fatty liver disease affects 25.2% of the global population⁵ and is defined as histologic evidence of hepatic steatosis alone. Obesity, dyslipidemia [high plasma triglyceride (TG) levels, low plasma concentrations of high-density lipoprotein cholesterol (HDL-C)], insulin resistance, glucose intolerance, T2DM, and hypertension are metabolic disorders that manifest hepatically as NAFLD.^{6,7} Furthermore, elevated oxidative stress can cause NAFLD by increasing lipid peroxidation and reactive oxygen species formation in hepatocytes.⁸ This, in turn, causes lipotoxicity and mitochondrial dysfunction.⁸ The most prevalent biochemical anomaly in NAFLD is elevated blood levels of transaminases, such as aspartate-aminotransferase (AST) and alanine-aminotransferase (ALT).⁷ From basic steatosis to cirrhosis as the final stage of liver disease, the pathogenesis of NAFLD is varied and complex.⁴ The liver undergoes metabolic-related alterations due to a variety of circumstances.⁴ Overnutrition can cause dysbiosis in the gastrointestinal system, and pro-inflammatory reactions can also be triggered by the liver's transfer of microbial-associated molecular processes.⁴ Genetic vulnerabilities to NAFLD development are increased by SNPs in PNPLA3 (rs738409, I148M).⁹ Within hepatocytes, this protein is located close to lipid droplets.¹⁰

Effective medication therapy is currently lacking, although the prevalence of NAFLD is steadily growing.⁶ In patients with NAFLD, the two main causes of death are cardiovascular disease and cancer.¹¹ Thus, the primary objective of treatment is to lower the risk of cardiovascular disease, cancer, hepatic steatosis, and inflammation. It is important to remember that most liver disease treatments are not yet approved. As an alternative, probiotics (Lactobacilli, Lactobacillus bulgaricus, and Streptococcus thermophilus) decrease liver enzymes but not liver steatosis in patients with NAFLD.¹² Moreover, Mediterranean diets and taking supplements

containing probiotics, antioxidants, polyphenols, or certain nutrients with hepatoprotective effects may help lower the progression of hepatic steatosis and improve liver enzyme levels in NAFLD.^{6,13} Probiotics are not, however, typically advised for the treatment of patients with NAFLD.⁴ Every patient with NAFLD must undergo lifestyle modification as an additional intervention. Within a year following a suggested lifestyle modification, Vilar-Gomez et al. demonstrated a decrease in hepatic steatosis and inflammation.¹⁴ Obese people with NAFLD benefit most from lifestyle changes. ^{6,14,15} Hepatic fibrosis and inflammation can be reversed with a consistent weight decrease of approximately 7%^{14,15}; however, there is no evidence to support the idea that weight loss helps lean patients.^{6,14,15} In addition to physical activity to reduce liver fat, patients are advised to abstain from alcohol consumption and excessive fructose intake.⁴ However, because patients require a change in behavioral patterns, regular physical activity and long-term weight loss are difficult.^{4,14,15} Other drugs that may reduce liver fat include sodium-glucose transporter 2 (SGLT2) inhibitors, such as empagliflozin.^{16,17} After receiving norursodeoxycholic acid for 12 weeks, a study found that ALT decreased.¹⁶ As an agonist of the peroxisome proliferator-activated receptor- γ , pioglitazone possesses anti-inflammatory and antifibrotic activities and can mitigate liver fibrosis and NAFLD.^{16,17} Another medication is phosphatidylcholine, which protects the liver from damage caused by oxidative stress.¹⁸ Nevertheless, these effects can be reversed if drug use is stopped. Therefore, treating NAFLD, particularly incurable NASH, is an urgent medical need.

Silymarin has been found as a therapeutic option for NAFLD as an additional possible therapy.^{6,19} Milk thistle (Silybum marianum) is a source of silymarin, a strong liver-tropic antioxidant.¹⁹ Among its many hepatoprotective benefits are enhanced protein synthesis, cell regeneration, antioxidant activity, and anti-inflammatory and antifibrotic abilities.⁶ By describing the effects of silymarin on blood biochemical indices, liver enzymes, fatty liver scores, and BMI, this meta-analysis examined the effectiveness of silymarin either alone or in conjunction with lifestyle changes or medications in patients with NAFLD.

MATERIALS AND METHODS

Methods

The Preferred Reporting Items for Systemic Reviews and Meta-Analysis (PRISMA) guidelines were followed in the conduct of this meta-analysis. This systematic review is registered as PROSPERO CRD42025633115. Ethical approval for this study was waived by the Ethics Committee of Philippine Women's University because this study was a meta-analysis without patient involvement.

Search strategy

PubMed, Embase, the Cochrane Library, Web of Science, clinicaltrails.gov, and the China National Knowledge Infrastructure were the sources from which pertinent articles were obtained. Records were retrieved from the databases using search terms pertaining to "silymarin", "nonalcoholic fatty liver disease", "lifestyle modifications", "mediterranean hypocaloric diet", and "anti-diabetic medication".

Study selection

Three researchers separately searched for and chose studies. After screening the titles and abstracts of the identified papers, the complete texts of possible studies were further evaluated in accordance with the eligibility requirements. Three authors compared the selected entire texts, and any differences or disagreements were discussed and settled.

Inclusion and exclusion criteria

Clinical trials were accepted if they met the following requirements: (1) Study design: RCTs; (2) Participants: NAFLD patients of any age, gender, or race; (3) Intervention: silymarin or silymarin complex, silymarin + lifestyle change, silymarin + Mediterranean hypocaloric diets, and silymarin + medicines; (4) Comparators: lifestyle modification, placebo, lifestyle modification, and medications (anti-diabetic drugs such as pioglitazone, diisopropylamine dichloroacetate (vitamin B15), polyene phosphatidylcholine (a more bioavailable form of phosphatidylcholine); (5) Outcomes: blood biochemical indicators [total cholesterol (TC), TG, HDL-C, low-density lipoprotein cholesterol (LDL-C), fasting blood glucose (FBG), and

homeostatic model assessment of insulin resistance (HOMA- IR); liver injury indicators [alanine aminotransferase (ALT) and aspartate aminotransferase (AST)]; liver histological indicators (hepatic steatosis grade); anthropometric indicator (body mass index, BMI); and (6) adverse effects (AEs), including headache, musculoskeletal disorders, fatigue, and difficulties with the heart, lungs, and gastrointestinal tract.

Exclusion criteria

Studies that (1) reported alcoholic steatohepatitis, alcoholic fatty liver, cirrhosis, or liver cancer; (2) received additional medication(s) or had a genetic predisposition (single nucleotide polymorphisms); (3) underwent liver transplantation; and (4) were based on conference papers, abstracts, non-original research, case reports, and non-peer-reviewed articles (e.g., conference materials and thesis) were excluded.

Quality assessment

Two authors independently evaluated the titles and abstracts of the obtained records to avoid irrelevant research. The full texts of selected publications were individually evaluated based on the eligibility criteria. The risk of bias in eligible RCTs was assessed using the Quality in Prognostic Studies (QUIPS) tool.²⁰ According to the Cochrane Methods Prognosis Group, the QUIPS tool is useful for prognostic research because it tackles potential biases in studies.²⁰ The six domains of the QUIPS tool are study confounding, study participation, study attrition, statistical analysis and reporting, outcome measurement, and prognostic factor measurement.²⁰ Low bias rates are observed in studies that provide comprehensive descriptions of the type of device, method of administration, power analysis, use of suitable statistical analysis, consideration of confounding variables, and interpretation of results (including bias causes). The overall risk of bias in these studies is moderate when there is some potential for bias but not enough to cause ambiguous findings. Cases with considerable biases are marked by numerous biases and serious faults that can render the judgment erroneous. At least two major errors in the design, analysis, or reporting process should be noted in high-risk research.²⁰ Two team members screened each study and determined its level of bias, which was classified as low, moderate, or high. To settle any possible disputes, an extra author was engaged in the review process. All studies, regardless of possible bias, were included.

Data synthesis and analysis

Meta-analyses were conducted using the Meta-mar tool. Given the various techniques used to quantify outcomes in each original investigation, continuous and categorical variables were aggregated using the standard mean difference (SMD) and odds ratio (OR), respectively. The statistical heterogeneity between studies was evaluated using the Cochran-Q test (I^2 statistic), which is the percentage of variance in the meta-analysis due to heterogeneity. The effects were estimated differently for each study, partly because of heterogeneity and random sampling errors.²¹ When heterogeneity substantially surpasses within-study sampling and measurement variability, the I² statistic reaches its maximum value of 1. If the I² was less than 50%, a fixed-effects model was used; otherwise, a random-effects model was used. Subgroup analyses were conducted to identify the source of heterogeneity. All statistical tests were considered significant at p < 0.05. A funnel plot was used to measure publication bias using Egger's regression test. Meta-regression analysis was also used to assess the heterogeneity (Q statistic) among the outcomes. The impact of each study on the total pooled effect estimate was assessed using a leave-one-out meta-analysis (OpenMeta-Analyst software). By investigating how the pooled effect estimate would have differed if each research were methodically eliminated, this methodology assessed the robustness of the meta-analysis findings.

RESULTS

Study selection

The search approach yielded a total of 1539 articles (until November 12, 2024), and the meta-analysis comprised 25 trials^{7,22-40} (Figure 1).

Basic characteristics and quality assessment

The meta-analysis included 25 trials and 2283 patients. Supplementary Table 1 summarizes the features of the included studies. The QUIPS tool indicated that 21 out of 25 studies had a

medium to high overall risk (Supplementary Table 2). The most problematic domains were statistical analysis and reporting and study confounding.

Total cholesterol (TC) levels

In patients with NAFLD, the overall effect of therapies decreased the TC levels (SMD: -0.84 (-1.25, -0.44), p=0.0005; Figure 2). A significant difference between the subgroups was found by the test for subgroup differences (p<0.01), indicating that the subgroups contributed differently to the total effect. There was significant heterogeneity among the studies included in this metaanalysis (I²=94%, p<0.01; Figure 2). Publication bias was not present in the studies according to the Funnel plot analysis using Egger's regression test (t=1.18, p=0.257, Supplementary Figure 1A). the meta-regression analysis showed high heterogeneity between outcomes (Q=185.291; p<0.0001; Supplementary Figure 1A).

Silymarin + medications (SMD: -1.12 (-1.67, -0.58), p<0.001) decreased TC, according to subgroup analysis. Total cholesterol levels were unaffected by using silymarin alone (SMD: -0.15 (-0.38, 0.07), p=0.183) or silymarin with lifestyle adjustment (SMD: -0.08 (-3.18, 1.56), p=0.280; Figure 2). Regarding the effect of therapies on TC, the sensitivity analysis indicated a moderate variability in the pooled effect estimate for the silymarin subgroup, revealing a moderate sensitivity of the meta-analysis to the exclusion of individual studies (Supplementary Figure 4A). Regarding the silymarin + medication subgroup, there was no variability in the pooled effect estimate, indicating a lack of sensitivity of the meta-analysis for the silymarin + lifestyle modification subgroup was not conducted because only three studies were included in the meta-analysis.

Blood TG levels

The overall effect of therapies decreased the TG levels in patients with NAFLD (SMD: -0.69 (-1.25, -0.13), p=0.020; Figure 3). Subgroups did not have any impact on the total effect observed, according to the test for subgroup differences, which showed no significant difference between subgroups (p=0.23). The studies included in this meta-analysis showed a

significant degree of heterogeneity ($I^2=97\%$, p<0.01; Figure 3). The studies had a modest publication bias, according to the Funnel plot analysis using Egger's regression test (t= -2.94, p<0.01; Supplementary Figure 1B). The meta-regression analysis showed high heterogeneity between outcomes (Q=503.505; p<0.0001; Supplementary Figure 1B).

According to subgroup analysis, silymarin + medication moderately decreased TG levels (SMD: -0.92 (-1.98, 0.14), p=0.081; Figure 3). The effects of silymarin (SMD: -0.20 (-0.79, 0.38), p=0.345) and silymarin + lifestyle modification (SMD: -0.69 (-1.87, 0.51), p=0.168) on TG levels were not significant (Figure 3). Regarding the effect of therapies on TGs, the sensitivity analysis indicated a variability in the pooled effect estimate for the silymarin and silymarin + medication subgroups, revealing the sensitivity of the meta-analysis to the exclusion of individual studies (Supplementary Figure 4B).

Blood HDL-C levels

The HDL-C levels in patients with NAFLD were not affected by the overall effect of the therapies (SMD: 0.28 (-0.21, 0.76), p=0.212; Figure 4). There was no significant difference between the subgroups, according to the test for subgroup differences (p=0.34), indicating that the subgroups had no bearing on the result that was achieved. There was a substantial degree of heterogeneity among the studies that were part of this meta-analysis (I²=69%, p<0.01; Figure 4). Egger's regression test, which was used to analyze the funnel plot, showed that there was no publication bias in the studies (t=0.42, p=0.691; Supplementary Figure 1C). Meta-regression analysis showed high heterogeneity between outcomes (Q=17.234; p=0.004; Supplementary Figure 1C).

Silymarin (SMD: 0.15 (-0.07, 0.38), p=0.188) and silymarin + lifestyle modification (SMD: 0.56 (-1.28, 2.39), p=0.320) did not affect HDL-C levels, according to subgroup analysis (Figure 4). Regarding the effect of therapies on HDL-C, the sensitivity analysis indicated a moderate variability in the pooled effect estimate for the silymarin subgroup, revealing a moderate sensitivity of the meta-analysis to the exclusion of individual studies (Supplementary Figure 5A). The leave-one-out meta-analysis for the silymarin + lifestyle

modification subgroup was not conducted because only three studies were included in the metaanalysis.

Blood LDL-C levels

In patients with NAFLD, the overall effect of interventions had no effect on LDL-C levels (SMD: -1.75 (-5.45, 1.96), p=0.292; Figure 5). There were no significant differences between the subgroups according to the test for subgroup differences (p=0.31), indicating that the subgroups had no effect on the result achieved. There was significant heterogeneity among the studies included in this meta-analysis (I²=93%, p<0.01; Figure 5). Egger's regression test-based Funnel plot analysis revealed that the studies had publication bias (t= - 5.05, p=0.004; Supplementary Figure 1D). Meta-regression analysis showed high heterogeneity between outcomes (Q=84.597; p<0.0001; Supplementary Figure 1D).

According to subgroup analysis, silymarin decreased LDL-C levels (SMD: -0.25 (-0.47, -0.03), p=0.027). Silymarin plus lifestyle changes (SMD: -3.89 (-19.43, 11.66), p=0.395) did not affect LDL-C levels (Figure 5). Regarding the effect of therapies on LDL-C, the sensitivity analysis indicated a variability in the pooled effect estimate for the silymarin subgroup, revealing the sensitivity of the meta-analysis to the exclusion of individual studies (Supplementary Figure 5B). The leave-one-out meta-analysis for the silymarin + lifestyle modification subgroup was not conducted because only three studies were included in the meta-analysis.

Fasting blood glucose (FBG) levels

The FBG levels in patients with NAFLD were unaffected by the overall effect of the therapies [SMD: -0.09 (-0.25, 0.08)], p=0.325; Figure 6). There was no significant difference between the subgroups, according to the test for subgroup differences (p=0.68), implying that the subgroups had no effect on the result obtained. Heterogeneity was low among the studies included in this meta-analysis (I²=0.0%, p=0.92; Figure 6). There was no publication bias in the studies according to the Funnel plot analysis using Egger's regression

test (t= -0.59, p=0.582; Supplementary Figure 2A). The meta-regression analysis showed no heterogeneity between outcomes (Q=1.140; p=0.768; Supplementary Figure 2A).

According to the subgroup analysis, silymarin (SMD: -0.05 (-0.30, 0.20), p=0.714) and silymarin + other therapies (Mediterranean hypocaloric diet, lifestyle modification, or medications) (SMD: -0.12 (-0.35, 0.11), p=0.672) had no effect on FBG (Figure 6). Regarding the effect of silymarin + other therapies on FBG, there was no variability in the pooled effect estimate, indicating a lack of sensitivity of the meta-analysis to the exclusion of individual studies (Supplementary Figure 5C). The leave-one-out meta-analysis for the silymarin subgroup was not conducted because only three studies were included in the meta-analysis.

Homeostatic model assessment of insulin resistance (HOMA-IR)

The HOMA-IR in patients with NAFLD was not affected by the overall effect of the therapies (silymarin, silymarin + Mediterranean hypocaloric diet, or Silymarin + medications) (SMD: -0.36 (-1.02, 0.29), p=0.174; Figure 7). The studies included in this meta-analysis showed a high degree of heterogeneity ($I^2=64\%$, p=0.04; Figure 7). Meta-regression analysis showed a lack of heterogeneity between outcomes (Q=0.083; p=0.773; Supplementary Figure2B). Regarding the effect of therapies on HOMA-IR, the sensitivity analysis indicated a variability in the pooled effect estimate, revealing the sensitivity of the meta-analysis to the exclusion of individual studies (Supplementary Figure 5D).

Body mass index (BMI)

The overall effect of the interventions decreased BMI in patients with NAFLD (SMD: -0.19 (-0.39, 0.00), p<0.05; Figure 7). Subgroups did not affect the overall effect achieved (p=0.78). There was low heterogeneity among the studies included in this meta-analysis (I²=33%, p=0.18; Figure 7). Publication bias was not present in the studies, according to the Funnel plot analysis using Egger's regression test (t= -0.20, p=0.848; Supplementary Figure 2C). The meta-regression analysis showed no heterogeneity between outcomes (Q=0.412; p=0.938; Supplementary Figure 2C).

Silymarin + lifestyle modification (SMD: -0.16 (-0.48, 0.16), p=0.331) and other therapies (silymarin, silymarin + Mediterranean hypocaloric diet, or silymarin + medication) had no effect on BMI (SMD: -0.21 (-0.46, 0.03), p=0.343; Figure 7). Regarding the effect of therapies on BMI, there was no variability in the pooled effect estimate, indicating a lack of sensitivity of the meta-analysis to the exclusion of individual studies (Supplementary Figure 5E). The leave-one-out meta-analysis for the silymarin + lifestyle modification subgroup was not conducted because only three studies were included in the meta-analysis.

Alanine transaminase (ALT) levels

The overall effect of the therapies decreased the ALT levels in patients with NAFLD (SMD: -0.73 (-1.25, -0.22), p=0.008; Figure 8). According to subgroup analysis, subgroups had no effect on the total effect observed (p=0.77; Figure 8). The studies included in this meta-analysis showed a significant degree of heterogeneity ($I^2=97\%$, p<0.01; Figure 8). Publication bias was not present in the studies, according to the Funnel plot analysis using Egger's regression test (t= -1.07, p=0.297; Supplementary Figure 2D). The meta-regression analysis showed heterogeneity between outcomes (Q=637.683; p<0.0001; Supplementary Figure 2D).

Silymarin + lifestyle modification (SMD: -0.88 (-1.09, -0.66), p<0.0001) or silymarin (SMD: -0.64 (-1.55, 0.26), p=0.120) had lower ALT levels than the comparator group, according to the subgroup analysis (Figure 8). The ALT levels in patients with NAFLD were unaffected by silymarin + medication (SMD: -0.69 (-1.91, 0.519), p=0.223; Figure 8). Regarding the effects of silymarin, silymarin + lifestyle modification, and silymarin + medication subgroups on ALT, the sensitivity analysis indicated a variability in the pooled effect estimate, revealing the sensitivity of the meta-analysis to the exclusion of individual studies (Supplementary Figure 6).

Aspartate aminotransferase (AST) levels

The AST levels in patients with NAFLD were decreased by the overall effect of the therapies (SMD: -1.06 (-1.54, -0.58), p=0.0002; Figure 9). The subgroup analysis showed no significant differences (p=0.32), indicating that the subgroups did not affect the overall effect (Figure 9). The studies included in this meta-analysis showed a significant degree of heterogeneity (I²=95%, p<0.01; Figure 9). Publication bias was not present in the studies according to the Funnel plot analysis using Egger's regression test (t=0.71, p=0.487; Supplementary Figure 3A). The meta-regression analysis showed heterogeneity between outcomes (Q=360.475; p<0.0001; Supplementary Figure 3A).

Silymarin + medication (SMD: -1.41 (-2.24, -0.59), p=0.005) or silymarin + lifestyle change (SMD: -0.72 (-1.49, -0.05), p=0.061) decreased AST levels compared with the comparator group (Figure 9). The AST levels were unaffected by silymarin (SMD: -0.88 (-2.45, 0.68), p=0.193; Figure 9). Regarding the effects of silymarin, silymarin + lifestyle modification, and silymarin + medication on AST, the sensitivity analysis indicated a variability in the pooled effect estimate, revealing the sensitivity of the meta-analysis to the exclusion of individual studies (Supplementary Figure 7A).

Fatty liver score

The fatty liver score in patients with NAFLD was moderately decreased by the overall effect of the therapies (Silymarin + medication, Mediterranean hypocaloric diet, or Silymarin) (SMD: -0.59 (-1.51, 0.33), p=0.133; Figure 10). The studies included in this meta-analysis showed a high degree of heterogeneity ($I^2=76\%$, p<0.01; Figure 10). Meta-regression analysis showed heterogeneity between outcomes (Q=8.48; p=0.004; Supplementary Figure 3B). Regarding the effects of therapies on fatty liver score, the sensitivity analysis indicated a variability in the pooled effect estimate, revealing the sensitivity of the meta-analysis to the exclusion of individual studies (Supplementary Figure 7B).

Hepatic steatosis rate

The overall effect of the therapies demonstrated a 55% decrease in the fatty liver rate in patients with NAFLD (SMD: 1.55 (1.08, 2.23), p=0.018; Figure 10). There was no difference between the subgroups according to the subgroup differences (p=0.58; Figure 10). This implies that the subgroups had no effect on the results achieved. There was low heterogeneity across the studies included in this meta-analysis (I²=0.0%, p=0.84; Figure 10). There was no publication bias according to the Funnel plot analysis using Egger's regression test (t=0.37, p=0.729; Supplementary Figure 3C). The meta-regression analysis showed lack of heterogeneity between outcomes (Q=1.235; p=0.872; Supplementary Figure 3C).

Silymarin + lifestyle modification (RR: 1.39 (0.91, 2.14), p=0.130) moderately decreased the hepatic steatosis rate by 39% (Figure 10). Other therapies, including silymarin or silymarin + Mediterranean hypocaloric diet, decreased the rate of hepatic steatosis by 103% (RR: 2.03 (1.03, 4.00); Figure 10).

Adverse effects

The use of silymarin increased the rate of patients with AEs by 98%, according to the metaanalysis (RR: 1.98 (1.11, 3.54), p=0.002; Figure 11A). However, 10 studies found no AEs among patients receiving medication, and only two trials documented AEs related to silymarin use. Among the silymarin group, gastrointestinal problems were the most frequent AEs (Figure 11B).

DISCUSSION

This meta-analysis demonstrated that interventions improved biochemical marker levels and hepatic steatosis rates in patients with NAFLD. However, subgroup analysis found that individual therapies, such as silymarin alone or in combination with lifestyle changes, Mediterranean hypocaloric diet and medications, had no consistent effect on patients with NAFLD.

This meta-analysis found that therapies including silymarin lowered BMI, biochemical indices (e.g., TC, TG, LDL-C, ALT, and AST), and improved HDL-C and hepatic steatosis rates in patients with NAFLD, consistent with earlier research.⁴¹ Dyslipidemia (high TC, TG, and LDL-C levels) is a significant risk factor for NAFLD.⁴² Furthermore, higher serum AST and ALT levels are the most common biochemical abnormalities in NAFLD.^{42,43} Currently, no specific medications have been licensed for NAFLD/NASH therapy; additionally, pharmacological treatments are only used in advanced NASH patients with fibrosis.⁷ In recent years, there has been an increasing focus on the therapeutic effects of numerous nutraceuticals for treating NAFLD.⁷ In this meta-analysis, we found that all therapies, including silymarin, improved the aforementioned metrics in patients with NAFLD. Silymarin is a liver-tropic antioxidant derived from milk thistle (Silybum marianum). This extract contains many antioxidants, the most abundant of which are silibin A and B and the flavonoid taxifolin.¹⁹ Silibinin reduces oxidative stress and inhibits PARP activation, thereby replenishing the NAD⁺ pool.⁴⁴ A mouse model demonstrated that silymarin reduced hepatic steatosis by regulating lipid metabolism and oxidative stress while simultaneously benefiting the circulatory system.⁴⁵ Silymarin's hepatoprotective effects include antioxidant activity, cell regeneration, enhanced protein synthesis, and anti-inflammatory and antifibrotic characteristics.⁴⁶ Furthermore, silymarin reduces the mRNA expression of enzymes in charge of de novo lipogenesis, such as sterol-regulatory element binding protein (SREBP1c), fatty acid synthetase, and acetyl-CoA carboxylase 1, which phosphorylates AMP-activated protein kinases in obese mice with diabetes and NAFLD.⁶ As a result, silymarin can enhance lipid metabolism and may be used as a therapy for NAFLD.⁶

This meta-analysis found that therapies (all trials included silymarin) had no effect on FBG levels or HOMA-IR in patients with NAFLD. The initial stage of NAFLD is fat deposition in the liver, which causes insulin resistance.⁴⁷ Insulin resistance and glucose metabolic dysfunction are common clinical signs of NAFLD, with increased blood glucose levels present in 70-80% of patients with NAFLD.⁶ Silymarin has been demonstrated to lower blood glucose, insulin, and HOMA-IR, although the precise mechanism by which it affects glucose levels is unknown.⁴⁸ Because silymarin is a potent antioxidant, its influence on glucose levels could be mediated by reducing lipid peroxidation.⁶ Silymarin was found to be beneficial in reducing insulin resistance in NAFLD, mostly by lowering visceral fat,

increasing lipolysis, and suppressing gluconeogenesis.⁴⁹ However, we found that treatment with silymarin did not affect FBG levels or HOMA-IR. This finding highlights the need for additional studies into the effects of silymarin on FBG levels and insulin resistance in patients with NAFLD.

In the following stage, we aimed to determine the effect of silymarin (monotherapy) and its combination with other therapies on NAFLD to better understand potential interactions or synergies between silymarin and other treatments. We found that silymarin monotherapy did not reduce TC, TG, or AST levels, whereas its combination with certain medications (including diisopropylamine dichloroacetate, polyene phosphatidylcholine, lovastatin, pioglitazone, or atorvastatin) significantly reduced TC, TG, and AST levels when compared with the comparator group that received these medications alone. Furthermore, silymarin alone did not reduce ALT levels, but when combined with Mediterranean diet or lifestyle modification, ALT levels were lower than in the group that received only Mediterranean diet or lifestyle modification. A randomized trial of 99 individuals found that silymarin administered 700 mg three times a day for 48 weeks did not diminish NAFLD.⁵⁰ NAFLD is a multisystem illness; thus, a combination therapy may be advantageous for patients with NAFLD.⁶ A randomized clinical trial found that silymarin, vitamin E, and a low-calorie diet decreased liver enzyme levels and non-invasive NAFLD.⁵¹ A study using overweight/obese patients with NAFLD that were treated with a Mediterranean-hypocaloric diet combined with nutraceutical supplementation (Vitamin E, L-glutathione, silymarin, and hepato-active compounds) showed that the use of specific supplements can improve the efficacy of interventions.⁷ These data suggest that the combination of silymarin and other therapies, such as Mediterranean diet, lifestyle modification, and medication, may affect the success of NAFLD treatment.

We also found that silymarin monotherapy, silymarin plus Mediterranean diet, and silymarin plus lifestyle modification decreased hepatic steatosis rates by 153% (two studies), 77% (one trial), and 39% (three studies), respectively. As previously stated, silymarin may reduce hepatic steatosis by regulating lipid metabolism and oxidative stress while also benefiting the circulatory system.⁵² Silymarin's hepatoprotective effects include antioxidant activity, cell regeneration, enhanced protein synthesis, and anti-inflammatory and antifibrotic characteristics.⁶ In addition, silymarin reduces the mRNA expression of enzymes

involved in de novo lipogenesis.⁵³ These findings suggest that silymarin could be a viable treatment to reduce hepatic steatosis rates.

To date, first-line therapy for NAFLD has been based on modifications to lifestyle (such as calorie restriction and physical activity) that result in weight loss.⁵⁴ However, our findings imply that combining lifestyle modification or medication with silymarin may enhance metabolism-related indices and reduce hepatic steatosis rates to a greater extent in patients with NAFLD. As previously stated, silymarin combined with lifestyle modification decreased the incidence of hepatic steatosis. The development of NAFLD is strongly linked to lifestyle variables, including high caloric consumption combined with low physical activity and exercise.⁵⁵ Global urbanization and modernization during the 20th and 21st centuries have been connected to unfavorable lifestyle changes.⁵⁵ Therefore, the mean worldwide BMI and obesity prevalence, which are the pathophysiological causes of NAFLD, have increased significantly during the previous three decades.⁵⁵ This is highlighted by the significant rise in the prevalence of NAFLD in Asia over the last 15 years, which is linked to urbanization and the use of "Western" foods.⁵⁶ Studies have shown that lifestyle management in patients with NAFLD reduces body weight, improves hepatic lipid content, and improves the NAFLD activity score (a composite of steatosis, inflammation, and hepatocyte ballooning).^{55,57} Of note, lifestyle modifications may be less effective for NAFLD resolution if the patient is severely obese (BMI \geq 35 kg/m²), has T2DM, or has severe NAFLD.58 Furthermore, persistent lifestyle modifications and weight loss are difficult to achieve, and lifestyle modifications alone are not effective in every case.

Although mild, this meta-analysis showed that a higher number of patients receiving silymarin developed AEs than those receiving alternative therapies. However, there is not much evidence of causality, and milk thistle is linked to some relatively mild AEs.⁵⁹ In a previous animal study, silymarin was orally administered to pregnant female mice.⁶⁰ At the conclusion of the trial, the fetal weight was lower than that of the control group, and silymarin exhibited teratogenic effects.⁶⁰ Abnormalities were noted in the skull, face, and vertebrae.⁶⁰ Because there is currently little evidence on silymarin's teratogenicity in pregnant humans and animals, more research is needed. Our results are consistent with those of other studies that indicated that silymarin was safe in humans at therapeutic dosages, with some trials reporting only temporary AEs, including gastrointestinal discomfort; however, further prenatal trials are

required. Furthermore, silymarin must be used carefully when taking medications with a limited therapeutic window because of possible interactions. To examine other medications, ingredients, or contaminants as possible causes, concurrent use of other medications should also be mentioned when AEs are noted.

Limitations

There were several limitations in this meta-analysis. Our understanding of the chronic nature of NAFLD may be limited because most of the included studies were cross-sectional. The inclusion of biased studies was another limitation of this meta-analysis. The majority of the studies included in this analysis had a moderate to high risk of bias, namely in the areas of statistical analysis, reporting, and study confounding. The majority of these studies lacked adequate data presentation to evaluate the suitability of the analytical approach, and statistical analysis was inappropriate in these investigations. Furthermore, insufficient information was available to determine whether the selected statistical model was suitable for the study design. Important potential confounders like sex, age, income, marital status, comorbidities, and educational attainment were not considered in the study design or analysis. Because the connections between the interventions and these potential confounders were not corrected, the result was probably misleading by confusing factors. Consequently, values that do not accurately represent the relationship are produced. In this situation, it is possible to make a false positive (Type I) error or draw the incorrect conclusion that the dependent variables and the independent variables are causally associated.⁶¹ Therefore, the validity of causal inference (internal validity) is seriously damaged by confounding.⁶¹ The small number of studies in each group and the high level of heterogeneity were additional limitations of this study. The high heterogeneity in this meta-analysis may be explained by the use of different interventions in the comparator group, including different hypocaloric Mediterranean diets, broad lifestyle changes (e.g., alcohol consumption, high fructose intake, and physical activity), or different medications (e.g., phosphatidylcholine or pioglitazone), in addition to different doses of silymarin use (e.g., 70, 94, 140, or 285 mg/day).

Conclusions

This meta-analysis demonstrated that silymarin-based therapies can relieve NAFLD. However, subgroup analysis found that individual therapies, such as silymarin alone or in combination with lifestyle changes, a hypocaloric Mediterranean diet, and medication, had no consistent effect on NAFLD. The optimal strategy for silymarin combination with other treatments should be determined in future investigations.

DATA AVAILABILITY STATEMENT

The data supporting the results of this study are available upon request from the corresponding author.

CONFLICT OF INTEREST AND FUNDING DISCLOSURE

The authors declare no potential conflicts of interest with respect to research, authorship, and/or publication of this article.

REFERENCES

- 1. Ludwig J, Viggiano TR, McGill DB, Oh BJ. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc. 1980;55:434-438.
- Gofton C, Upendran Y, Zheng MH, George J. MAFLD: How is it different from NAFLD? Clin Mol Hepatol. 2023;29(Suppl):S17-S31. doi: 10.3350/cmh.2022.0367.
- 3. Yamamura S, Eslam M, Kawaguchi T, Tsutsumi T, Nakano D, Yoshinaga S, et al. MAFLD identifies patients with significant hepatic fibrosis better than NAFLD. Liver Int. 2020;40:3018-3030. doi: 10.1111/liv.14675.
- 4. Grander C, Grabherr F, Tilg H. Non-alcoholic fatty liver disease: pathophysiological concepts and treatment options. Cardiovasc Res. 2023;119:1787-1798. doi: 10.1093/cvr/cvad095.
- Brunt EM. Pathology of nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol. 2010;7:195-203. doi: 10.1038/nrgastro.2010.21.
- Li S, Duan F, Li S, Lu B. Administration of silymarin in NAFLD/NASH: A systematic review and metaanalysis. Ann Hepatol. 2024;29:101174. doi: 10.1016/j.aohep.2023.101174.
- Chiurazzi M, Cacciapuoti N, Di Lauro M, Nasti G, Ceparano M, Salomone E, et al. The synergic effect of a nutraceutical supplementation associated to a Mediterranean hypocaloric diet in a population of overweight/obese adults with NAFLD. Nutrients. 2022;14:4750. doi: 10.3390/nu14224750.

- Benedict M, Zhang X. Non-alcoholic fatty liver disease: An expanded review. World J Hepatol. 2017;9:715-732. doi: 10.4254/wjh.v9.i16.715.
- Romeo S, Kozlitina J, Xing C, Pertsemlidis A, Cox D, Pennacchio LA, et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet. 2008;40:1461-1465. doi: 10.1038/ng.257.
- BasuRay S, Wang Y, Smagris E, Cohen JC, Hobbs HH. Accumulation of PNPLA3 on lipid droplets is the basis of associated hepatic steatosis. Proc Natl Acad Sci USA. 2019;116:9521-9526. doi: 10.1073/pnas.1901974116.
- Ekstedt M, Hagstrom H, Nasr P, Fredrikson M, Stal P, Kechagias S, et al. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology. 2015;61:1547-1554. doi: 10.1002/hep.27368.
- Loguercio C, De Simone T, Federico A, Terracciano F, Tuccillo C, Di Chicco M, et al. Gut-liver axis: a new point of attack to treat chronic liver damage? Am J Gastroenterol. 2002;97:2144-2146. doi: 10.1111/j.1572-0241.2002.05942.x.
- Abenavoli L, Scarpellini E, Pellicano R, Fagoonee S, Larussa T, Luzza F. Mediterranean diet and probiotics supplementation to treat non-alcoholic fatty liver dis- ease. Minerva Med. 2020;111:526–528. doi: 10.23736/S0026-4806.20.07089-5.
- Vilar-Gomez E, Martinez-Perez Y, Calzadilla-Bertot L, Torres-Gonzalez A, Gra-Oramas B, Gonzalez-Fabian L, et al. Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis. Gastroenterology. 2015;149:367–378.e5. doi: 10.1053/j.gastro.2015.04.005.
- 15. Shira Zelber-Sagi, J. Bernadette Moore. Practical lifestyle management of nonalcoholic fatty liver disease for busy clinicians. Diabetes Spectr. 2024;37:39-47. doi: 10.2337/dsi23-0009.
- 16. Kuchay MS, Krishan S, Mishra SK, Farooqui KJ, Singh MK, Wasir JS, et al. Effect of empagliflozin on liver fat in patients with type 2 diabetes and nonalcoholic fatty liver disease: a randomized controlled trial (E-LIFT trial). Diabetes care. 2018;41:1801-1808. doi: 10.2337/dc18-0165.
- Bajaj M, Suraamornkul S, Piper P, Hardies LJ, Glass L, Cersosimo E, et al. Decreased plasma adiponectin concentrations are closely related to hepatic fat content and hepatic insulin resistance in pioglitazonetreated type 2 diabetic patients. J Clin Endocrinol Metab. 2004; 89:200–206. doi: 10.1210/jc.2003-031315.
- Kharbanda KK, Mailliard ME, Baldwin CR, Beckenhauer HC, Sorrell MF, Tuma DJ. Betaine attenuates alcoholic steatosis by restoring phosphatidylcholine generation via the phosphatidylethanolamine methyltransferase pathway. J Hepatol. 2007; 46:314-321. doi: 10.1016/j.jhep.2006.08.024.
- 19. Hajaghamohammadi A, Ziaee A, Rafiei R. The efficacy of silymarin in decreasing transaminase activities in non-alcoholic fatty liver disease: A randomized controlled clinical trial. Hepat Mon. 2008;8: 191-195.
- Kowsar R, Rahimi AM, Sroka M, Mansouri A, Sadeghi K, Bonakdar E, et al. Risk of mortality in COVID-19 patients: a meta- and network analysis. Sci Rep. 2023;13:2138. doi: 10.1038/s41598-023-29364-8.

- von Hippel PT. The heterogeneity statistic I(2) can be biased in small meta-analyses. BMC Med Res Methodol. 2015;15:35. doi: 10.1186/s12874-015-0024-z.
- 22. Abenavoli L, Greco M, Nazionale I, Peta V, Milic N, Accattato F, et al. Effects of Mediterranean diet supplemented with silybin-vitamin E-phospholipid complex in overweight patients with non-alcoholic fatty liver disease. Expert Rev Gastroenterol Hepatol. 2015;9:519–527. doi: 10.1586/17474124.2015.1004312.
- Anushiravani A, Haddadi N, Pourfarmanbar M, Mohammadkarimi V. Treatment options for nonalcoholic fatty liver disease: A double-blinded randomized placebo-controlled trial. Eur J Gastroenterol Hepatol. 2019;31:613–617. doi: 10.1097/MEG.00000000001369.
- 24. Ataee Z, Vahabzadeh M, Kiapey SSM, Rahimi HR, Mozaffari HM, Ziaee MJHMJ. Triple therapy with garlic, silymarin and curcumin in non-alcoholic fatty liver disease: A randomized, placebo-controlled clinical trial. Herb Med J. 2021;6:50-64. doi: 10.22087/hmj.v6i2.917.
- Kheong CW, Mustapha NRN, Mahadeva SJCG. A randomized trial of silymarin for the treatment of nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol. 2017;15:1940-1949. doi: 10.1016/j.cgh.2017.04.016.
- 26. Curcio A, Romano A, Cuozzo S, Di Nicola A, Grassi O, Schiaroli D, et al. Silymarin in combination with vitamin C, vitamin E, coenzyme Q10 and selenomethionine to improve liver enzymes and blood lipid profile in NAFLD patients. Med Lithuania Medicina. 2020;56:544. doi: 10.3390/medicina56100544.
- 27. Famouri F, Salehi M-M, Rostampour N, Hashemi E, Shahsanaee A. The effect of silymarin on nonalcoholic fatty liver disease of children. J Herbmed Pharmacol. 2016;6:16–20.
- 28. Hashemi SJ, Hajiani E, Sardabi EH. A placebo-controlled trial of silymarin in patients with nonalcoholic fatty liver disease. Hepat Mon. 2009;9: 265-270.
- 29. Mirhashemi SH, Hakakzadeh A, Yeganeh FE, Oshidari B, Rezaee SP. Effect of 8 weeks milk thistle powder (silymarin extract) supplementation on fatty liver disease in patient candidates for bariatric surgery. Metab Open. 2022;14. doi: 10.1016/j.metop.2022.100190.
- Navarro VJ, Belle SH, D'Amato M, Adfhal N, Brunt EM, Fried MW, et al. Silymarin in non-cirrhotics with non-alcoholic steatohepatitis: a randomized, double-blind, placebo-controlled trial. PLoS One 2019;14. doi: 10.1371/journal.pone.0221683.
- 31. Rajendra VKP, Kurapati S, Balineni SK, Gogineni NTT. Disease. A blend of Sphaeranthus indicus flower head and Terminalia Chebula fruit extracts reduces fatty liver and improves liver function in non-alcoholic, overweight adults. Funct Foods Health Dis. 2022;12:361-179. doi: 10.31989/ffhd.v12i7.958.
- 32. Shaikh KR, Shaikh S, Ata MA, Memon A, Soomro UA, Siddidui SS. Therapeutic efficacy of Silymarin on liver aminotransferases in patients with nonalcoholic fatty liver disease. Rawal Med J. 2021;46:761–764.
- 33. Solhi H, Ghahremani R, Kazemifar AM, Hoseini Yazdi Z. Silymarin in treatment of non-alcoholic steatohepatitis: a randomized clinical trial. Caspian J Internal Med. 2014;5:9–12.

- 34. Chen L. Effect of silybin in the treatment of non-alcoholic fatty liver disease. China Med Eng. 2012;20:141–145.
- 35. Cui Z, C. Effect of silybin combined with compound diisopropylamine dichloroacetate on nonalcoholic fatty liver. Henan Med Res. 2020;29:3172–3173.
- 36. Yong J, Yulong G, Xiaoling H, Qun L, Xu Z. Clinical trial of bifid triple viable powder combined with silibinin capsules in the treatment of patients with non alcoholic fatty liver disease. Chin J Clin Pharmacol. 2020;36:2212–2215.
- 37. Li CL. Silybin combined with compound diisopropylamine dichloroacetate on the liver of patients with nonalcoholic fatty liver effects of changes in function and lipid levels. J North Pharm. 2018;15:85–86.
- Li HQ, Si Y. Analysis of silybin in the treatment of non-alcoholic steatohepatitis. Chin J Prac Nerv Dis. 2010;13:37–38.
- 39. Li SL. To explore the therapeutic effect of polyene phosphatidylcholine combined with silybin in the treatment of nonalcoholic fatty liver. J North Pharm. 2018;15:65.
- 40. Liang CP, Liu QM, Zhong YL. Efficacy of silybin combined with lovastatin in the treatment of nonalcoholic fatty liver. J Mudanjiang Med Univ. 2015;36:76–77.
- 41. Ebrahimpour-Koujan S, Gargari BP, Mobasseri M, Valizadeh H, Asghari-Jafarabadi MJP. Lower glycemic indices and lipid profile among type 2 diabetes mellitus patients who received novel dose of Silybum marianum (L.) Gaertn. (silymarin) extract supplement: A Triple-blinded randomized controlled clinical trial. Phytomedicine. 2018;44:39-44. doi: 10.1016/j.phymed.2018.03.050.
- 42. Liangpunsakul S, Chalasani N. Unexplained elevations in alanine amino- transferase in individuals with the metabolic syndrome: results from the third National Health and Nutrition Survey (NHANES III). Am J Med Sci. 2005;329:111-116. doi: 10.1097/00000441-200503000-00001.
- 43. Oh RC, Hustead TR, Ali SM, Pantsari MW. Mildly elevated liver transaminase levels: causes and evaluation. Am Fam Physician. 2017; 96:709–715.
- 44. Salomone F, Barbagallo I, Godos J, Lembo V, Currenti W, Cina D, et al. Silibinin restores NAD(+) levels and induces the SIRT1/AMPK pathway in non-alcoholic fatty liver. Nutrients. 2017;9:10. doi: 10.3390/nu9101086.
- 45. Ni X, Wang H. Silymarin attenuated hepatic steatosis through regulation of lipid metabolism and oxidative stress in a mouse model of nonalcoholic fatty liver disease (NAFLD). Am J Transl Res. 2016;8:1073-1081.
- 46. Saller R, Brignoli R, Melzer J, Meier R. An updated systematic review with meta-analysis for the clinical evidence of silymarin. Forsch Komplementmed. 2008;15:9-20. doi: 10.1159/000113648.
- 47. Chalasani N, Younossi Z, Lavine JE, Charlton M, Cusi K, Rinella M, et al. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018;67:328-357. doi: 10.1002/hep.29367.

- 48. Pouwels S, Sakran N, Graham Y, Leal A, Pintar T, Yang W, et al. Non-alcoholic fatty liver disease (NAFLD): a review of pathophysiology, clinical management and effects of weight loss. BMC Endocr Disord. 2022;22:63. doi: 10.1186/s12902-022-00980-1.
- Ghalandari K, Shabani M, Khajehlandi A, Mohammadi A. Effect of aerobic training with silymarin consumption on glycemic indices and liver enzymes in men with type 2 diabetes. Arch Physiol Biochem. 2023;129:76-81. doi: 10.1080/13813455.2020.1797104.
- 50. Yao J, Zhi M, Gao X, Hu P, Li C, Yang X. Effect and the probable mechanisms of silibinin in regulating insulin resistance in the liver of rats with non-alcoholic fatty liver. Braz J Med Biol Res. 2013;46:270-277. doi: 10.1590/1414-431X20122551.
- 51. Aller R, Izaola O, Gómez S, Tafur C, González G, Berroa E, et al. Effect of silymarin plus vitamin E in patients with non-alcoholic fatty liver disease. A randomized clinical pilot study. Eur Rev Med Pharmacol Sci. 2015;19:3118-3124.
- Wah Kheong C, Nik Mustapha NR, Mahadeva S. A randomized trial of Silymarin for the treatment of nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol. 2017;15:1940-1949. doi: 10.1016/j.cgh.2017.04.016.
- 53. Sahin E, Bagci R, Aykanat NEB, Kacar S, Sahinturk V. Silymarin attenuated nonalcoholic fatty liver disease through the regulation of endoplasmic reticulum stress proteins GRP78 and XBP-1 in mice. J Food Biochem. 2020;44:e13194. doi: 10.1111/jfbc.13194.
- 54. Fernández T, Viñuela M, Vidal C, Barrera F. Lifestyle changes in patients with non-alcoholic fatty liver disease: A systematic review and meta-analysis. PLoS ONE 2022;17:e0263931. doi: 10.1371/journal.pone.0263931.
- 55. Hallsworth K, Adams LA. Lifestyle modification in NAFLD/NASH: Facts and figures. JHEP Rep. 2019;1:468-479. doi: 10.1016/j.jhepr.2019.10.008.
- 56. Li J, Zou B, Yeo YH, Feng Y, Xie X, Lee DH, et al. Prevalence, incidence, and outcome of non-alcoholic fatty liver disease in Asia, 1999-2019: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2019;4:389-398. doi: 10.1016/S2468-1253(19)30039-1.
- 57. St George A, Bauman A, Johnston A, Farrell G, Chey T, George J. Effect of a lifestyle intervention in patients with abnormal liver enzymes and metabolic risk factors. J Gastroenterol Hepatol. 2009;24:399– 407. doi: 10.1111/j.1440-1746.2008.05694.x.
- Vilar-Gomez E, Martinez-Perez Y, Calzadilla-Bertot L, Torres-Gonzalez A, Gra-Oramas B, Gonzalez-Fabian L, et al. Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis. Gastroenterology. 2015;149:367-378. doi: 10.1053/j.gastro.2015.04.005.
- 59. Soleimani V, Sadat Delghandi P, Moallem SA, Karimi G. Safety and toxicity of silymarin, the major constituent of milk thistle extract: An updated review. Phytother Res. 2019;1-12. doi: 10.1002/ptr.6361.
- 60. Gholami M, Moallem SA, Afshar M, Amoueian S, Etemad L, Karimi G. Teratogenic effects of silymarin on mouse fetuses. Avicenna J Phytomed. 2016;6:542–549.

 Pourhoseingholi MA, Baghestani AR, Vahedi M. How to control confounding effects by statistical analysis. Gastroenterol Hepatol Bed Bench. 2012;5:79-83.





Figure 1. PRISMA flow chart of the studies included in the meta-analysis.

Total cholesterol A) Silvmarin

A) Shyman	1						
	Experimenta	ul 👘 👘	Control		Std. Mean Difference	Std. Mean Difference	
Study	Mean S	D Total Mean	SD Total	Weight	IV, Fixed, 95% CI	IV, Fixed, 95% CI	
Ataee 2021	-1.19 40.340	0 24 -7.07	32.4800 26	16.3%	0.16 [-0.40; 0.71]		
Chan 2017	-0.33 1.270	0 49 -0.09	0.8800 50	32.3%	-0.22 [-0.61; 0.18]		
Raiendra 2022	-11.05 28.430	0 29 5.50	32,4000 30	18.6%	-0.54 [-1.06: -0.02] -		
Hashemi 2009	3 24 59 600	0 50 4 64	52 9700 50	32.8%	-0.02 [-0.42: 0.37]		
Thuomonin 2000	0.21 00.000		02.07.00 00	02.070	0.02[0.12, 0.01]		
Total (95% CI)		152	156	100.0%	-0 15 [-0 38 0 07]		
Heterogeneity: Ta	u ² - 0.0028. Ch ²	- 3 80 df - 3 /0	$P = 0.28 \cdot 1^2 = 219$	100.070	-0.10[-0.00, 0.07]		
Therefogeneity. Ta	u = 0.0020, Olli	- 0.00, 01 - 0 (1	= 0.20), 1 = 21 /	•	P=0 183	0.5 0 0.5	1
					1 0.100	-0.5 0 0.5	
						Exp CNT	
B) Silvmarin	+ ifestyle	modificat	ion				
D) Shymann	I I Ellestyle	mounicat					
	Experime	ental	Control		Std. Mean Difference	Std. Mean Difference	•
Study	Mean	SD Total M	ean SD To	tal Weig	ht IV, Random, 95% CI	IV, Random, 95% CI	
Anushiravani 20	19 -1.40 43.4	4000 30 -7	7.00 52.0600	30 33.5	% 0.12 [-0.39; 0.62]		
Curcio 2020	-35.46 33.0	0700 41 -12	2.33 25.6800	40 34.0	% -0.77 [-1.22; -0.32]		
Chen 2012	-1.25 0.1	1700 30 -0	0.86 0.2500	30 32.5	% -1.80 [-2.41; -1.19]		
Total (95% CI)		101	1	00 100.0	% -0.81 [-3.18; 1.56]		
Heterogeneity: Tau	$i^2 = 0.8275$; Chi ² =	22.73, df = 2 (P	< 0.01); I ² = 91%		• • • •		
					P=0.280	-3 -2 -1 0 1 2	3
						Exp CNT	
C) Silvmarin	+ Medicati	on					
,,	Exportmontal		Control		td Mean Difference	Std Maan Difference	
Study	Moon SD	Total Moon	SD Total	Moight	V Pandom 05% Cl	IV Pandom 95% Cl	2
Siduy	Wear SD	Iotal weall	SD IOIAI	o og/	105 (1 71: 0 70)	IV, Handoni, 95% CI	
Cui 2020	-2.62 1.0100	44 -1.42	0.8900 44	9.8%	-1.25 [-1.71; -0.79]		
LI 2018	-2.65 1.3100	48 -1.50	1.2100 48	10.0%	-0.86 [-1.28; -0.44]		
Lisneng 2018	-1.80 0.6900	50 -0.60	0.6600 48	9.8%	-1.76 [-2.23; -1.29]		
Liang 2015	-1.54 0.3900	45 -0.87	0.7700 45	9.9%	-1.09 [-1.53; -0.64]		
Liu 2012	-0.95 1.4200	42 -0.29	1.5400 34	9.8%	-0.44 [-0.90; 0.01]		
Wang 2013	-4.80 1.0800	65 -3.70	1.2800 65	10.2%	-0.92 [-1.29; -0.56]		
Xiao 2019	-3.40 0.5300	150 -1.70	0.6200 150	10.3%	-2.94 [-3.27; -2.61] 🚦	-	
Yang 2020	-3.60 1.9800	70 -2.31	2.0200 70	10.3%	-0.64 [-0.98; -0.30]		
Zhang2018	-0.90 1.0800	50 -0.50	1.1500 50	10.1%	-0.36 [-0.75; 0.04]		
Zhao 2008	-0.72 0.3800	50 -0.34	0.4400 34	9.8%	-0.93 [-1.39: -0.47]		
					1		
Total (95% CI)		614	588 1	00.0%	-1 12 [-1 67: -0 58]		
Heterogeneity: T	au ² - 0 5490. Ch	2 - 158 76 df -	9 (P < 0.01) 12	9.4%			1
rictorogeneity. In	au = 0.0450, 011	- 150.70, ui -	. 5 (1 < 0.01), 1 -	- 5470	P=0.001		2
					F=0.001		3
						LAP CNI	
Total /95% Ch		867		44 100 0	% _0.84 [-1.250.44]	_	
10tal (55% CI)	2 0 5775 0: 2	007	0	44 100.0	/0 -0.04 [-1.25; -0.44]		_
Heterogeneity: Tai	J = 0.5775; Chi [*] =	248.99, df = 16	$P < 0.01$; $\Gamma = 94\%$	0			÷.
				-			

Figure 2. The forest plot shows the effect of various treatments (Exp) on total cholesterol levels in blood compared with the comparator control (CNT) in patients with NAFLD.



CNT

Exp

Triglycerides

ingrycenaes									Fig. 3
A) Silymarin	Exp	erimental			Control			Std. Mean Difference	Std. Mean Difference
Study	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI
Ataee 2021	3.78	82.3000	24	-26.93	75.2700	26	20.6%	0.38 [-0.18; 0.94]	
Chan 2017	-0.20	0.5000	49	0.04	0.4300	50	28.2%	-0.51 [-0.91; -0.11] -	
Rajendra 2022	-3.86	35.5700	29	10.04	59.1300	30	22.6%	-0.28 [-0.79; 0.23]	
Hashemi 2009	-21.32	110.1400	50	7.20	102.3500	50	28.6%	-0.27 [-0.66; 0.13]	
Total (95% CI) Heterogeneity: Ta	w ² – 0.04	67 [.] Chi ² – f	152	-3(P-	0.09\·1 ² - 5	156	100.0%	-0.20 [-0.79; 0.38]	
notorogeneity. Ta	- 0.01	, on - e			0.007,1 = 0			P=0.345	^{-0.5} Exp ⁰ CNT ^{0.5}

B) Silymarin + Lifestyle modification



C) Silymarin + Medication

	Exper	imental			Control			Std. Mean Difference	Э	Std. Me	an Dif	ferenc	e	
Study	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI		IV, Rar	ndom,	95% C	1	
Cui 2020	-1.75	0.3100	44	-0.99	0.2900	44	10.9%	-2.51 [-3.07; -1.95]	-	-				
Li 2018	-1.76	0.3600	48	-0.91	0.3300	48	11.0%	-2.44 [-2.97; -1.91]	-	-				
Lisheng 2018	-0.90	0.5300	50	-0.20	0.5600	48	11.1%	-1.27 [-1.71; -0.84]						
Liang 2015	-1.45	0.7100	45	-0.79	0.8300	45	11.1%	-0.85 [-1.28; -0.42]			-			
Liu 2012	-1.61	1.1700	42	-0.28	1.2700	34	11.0%	-1.08 [-1.57; -0.60]		-	-			
Wang 2013	-3.10	1.7100	65	-1.40	1.5700	65	11.2%	-1.03 [-1.40; -0.66]		-				
Xiao 2019	-1.30	0.4600	150	-2.30	0.4400	150	11.3%	2.22 [1.93; 2.50]					-	
Yang 2020	-0.97	0.4900	70	-0.52	0.3900	70	11.2%	-1.01 [-1.36; -0.66]		-				
Zhang2018	-0.80	0.7200	50	-0.50	0.8200	50	11.2%	-0.39 [-0.78; 0.01]		-	-			
Total (95% CI) Heterogeneity: T	au ² = 1.	8620: Ch	564 1 ² = 476	6.46. df	= 8 (P < 0	554	100.0% = 98%	-0.92 [-1.98; 0.14]	—	-		-	1	٦
								P=0.080	-3	-2 -1	0	1	2	3
										Exp		CN	Т	
Total (95% CI)	2 - 1 12	70: Chi ² -	509 27	847	(D < 0.0)	1)- 12 - 0	830 10	0.0% -0.69 [-1.25; -0	.13]		-			_
Test for subgroup	lifference	$r_0, Chi^2 =$	2 93 d	f = 2 (P)	= 0.23)	1), 1 - 5	Overall	effect: D=0.020		-3 -2 .	-1 0	1	2	3
rest ist subgroup (amerene	00. 011	2.00, 0	(1	0.20)		overall	Circol. 1 =0.020		~ 2 Eve		CNI	-	0
										Exp		CN		

Figure 3. The forest plot shows the effect of various treatments (Exp) on blood triglyceride levels compared with the comparator control (CNT) in patients with NAFLD.

2

HDL

A) Silymarin	Expe	rimental		(Control			Std. Mean Difference	Std. Mea	Fig. 4 an Difference
Study	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% CI	IV. Fix	ed. 95% CI
Ataee 2021	0.87	11.7800	24	3.66	6.1600	26	16.2%	-0.30 [-0.85: 0.26]		
Chan 2017	0.07	0.1500	49	0.02	0.1700	50	32.1%	0.31 [-0.09; 0.71]		
Rajendra 2022	0.90	5.4200	29	1.24	3.8000	30	19.4%	-0.07 [-0.58; 0.44]		
Hashemi 2009	0.32	5.4900	50	-1.66	5.6900	50	32.3%	0.35 [-0.04; 0.75]		
Total (95% CI) Heterogeneity: Ta	$u^2 = 0.0$	307: Chi ²	152 = 4.79.	df = 3 (F	P = 0.19)	156 1 ² = 37	100.0% %	0.15 [-0.07; 0.38]	I	+
						,,		P=0.188	-0.5	0 0.5
							1.221		Exp	CNT
							C)			
B) Silymarin	+ Lite	estyle n	nodifi	cation	1	1.20			1212 2722	12.110
	E	Experime	ntal		Contr	ol	0.1555.5175	Std. Mean Difference	Std. Mea	n Difference
Study	M	ean	SD To	tal Mea	in S	D Tota	al Weigh	t IV, Random, 95% CI	IV, Rand	om, 95% CI
Anushiravani 20	19 (0.10 11.4	500	30 -0.3	30 7.710	00 3	0 33.7%	6 0.04 [-0.47; 0.55]	-	
Curcio 2020		0.38 10.4	900	41 4.0	0 0.500	0 4	0 34.97	6 0.27 [-0.17; 0.71]		
LI 2010	(0.60 0.2	200	30 0.2	20 0.250	0 2	0 31.47	6 1.44 [0.80; 2.08]		
Total (95% CI)			1	01		9	0 100.09	6 0.56 [-1.28; 2.39]		
Heterogeneity: Tau	$J^2 = 0.45$	56; Chi ² =	12.44, d	if = 2 (P -	< 0.01); l ²	= 84%			1 1	1 1 1
								P=0.320	-2 -1 Exp	0 1 2 CNT
Total (95% CI) Heterogeneity: Ta	u ² = 0.17	766; Chi ² =	2 19.60, d	2 53 df = 6 (P	< 0.01); l	24 2 = 69%	6 100.0%	6 0.28 [-0.21; 0.76]		+
Test for subgroup	differend	ces: Chi ² =	0.93, df	= 1 (P =	0.34)	Ov	erall ef	fect: P=0.212	-2 -1 Exp	0 1 2 CNT

Figure 4. The forest plot shows the effect of various treatments (Exp) on HDL-C levels compared with the comparator control (CNT) in patients with NAFLD.

LDL

A) Silymarin										Fig. 5
	Expe	rimental			Control			Std. Mean Difference	Std. Me	an Difference
Study	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% CI	IV, Fi	xed, 95% CI
Ataee 2021	-3.39	39.3900	24	7.04	27.2800	26	16.2%	-0.31 [-0.86; 0.25]		
Chan 2017	-0.31	1.2100	49	-0.17	0.7700	50	32.4%	-0.14 [-0.53; 0.26]		
Rajendra 2022	-11.17	25.4500	29	1.00	25.3200	30	18.8%	-0.47 [-0.99; 0.04]		
Hashemi 2009	-2.88	49.0900	50	7.60	47.4500	50	32.6%	-0.22 [-0.61; 0.18]		
Total (95% CI)	$u^2 = 0.0$	$hi^2 = 1.09$	152 df - 3	(P = 0.7	(8): 1 ² - 0%	156	100.0%	-0.25 [-0.48; -0.03]		
Therefogonolity. Tax	0, 0	111 - 1.00,	01 - 01	(1 = 0.7	0,,1 = 0,8			P=0.027	-0.5	0 0.5
										CNT
B) Silymarin	+ Lifes	style mo	dific	ation						
	E	periment	al		Contro	ol .		Std. Mean Difference	Std. Mean	Difference
Study	Me	an S	D Tota	al Mea	n SE) Total	Weight	IV, Random, 95% CI	IV, Rando	m, 95% Cl
Anushiravani 201	9 -0.	90 38.800	00 3	0 -0.6	0 44.1900	30	33.7%	-0.01 [-0.51; 0.50]		
0	00	CO 10 500	10 1		1 01 0000	1 10	00 70/	0.001 4 40. 0.001		

Test for subgroup diffe	erences: Chi [*] = 1.01, d	f = 1 (P = 0.31)	Overall	effect: P=0.292	-15 -10 -5 Exp	0	5 10 CNT) 15
Total (95% CI) Heterogeneity: Tau ² =	= 14.7969; Chi ² = 87.45	253 , df = 6 (P < 0.01); l ² = 9	246 100.09 93%	。 -1.75 [-5.45; 1.96]		+		
				P=0.395	-15 -10 -5 Exp	0	5 10 CNT	15
Total (95% CI) Heterogeneity: Tau ² =	= 38.1723; Chi ² = 83.50	101 , df = 2 (P < 0.01); I ² = 9	90 100.0% 98%	-3.89 [-19.43; 11.66]			1 1	
Curcio 2020 Li 2010	-26.69 19.5800 -1.43 0.0800	41 -11.44 24.6900 30 -0.60 0.0600) 40 33.7%) 20 32.5%	-0.68 [-1.13;-0.23] -11.23 [-13.59;-8.87]	-	1		

Figure 5. The forest plot shows the effect of various treatments (Exp) on LDL-C levels compared with the comparator control (CNT) in patients with NAFLD.

FBG A) Silvmarin									Fig	jure 6		
Study or Subgroup	Experimenta Mean SI	l) Total	Mean	Control SD	Total	Weight	Std. Mean Difference IV, Fixed, 95% CI	•	Std. Me IV, Fit	an Dif xed, 95	ference 5% Cl	
subgroup = subgrou	ip1											
Ataee 2021	-0.73 10.740	24	-1.91	13.8600	26	9.3%	0.09 [-0.46; 0.65]					
Chan 2017	0.30 1.610) 49	0.70	2.0900	50	18.4%	-0.21 [-0.61; 0.18]		-			
Hashemi 2009	2.38 46.920	50	0.20	45.0700	50	18.7%	0.05 [-0.35; 0.44]		_	+	_	
Total (95% CI)		123			126	46.4%	-0.05 [-0.30; 0.20]		-			
Heterogeneity: Tau ² = 0	; Chi ² = 1.14, df =	2 (P = 0	.57); l ²	= 0% P=0 .	714							
B) Silymarin + other ther Subgroup = Subgrou	apies ip2											
Abenavoli 2015	-10.47 18.660	0 10	-7.11	14.4600	10	3.7%	-0.19 [-1.07; 0.69]	_		•+		
Chiurazzi 2022	-12.60 22.560	36	-8.30	19.6500	32	12.6%	-0.20 [-0.68; 0.28]			•	-	
Anushiravani 2019	-11.90 14.460	30	-6.80	26.6700	30	11.1%	-0.23 [-0.74: 0.27]			• • +	-	
Yang 2020	-0.09 1.070	70	-0.07	1.0400	70	26.2%	-0.02 [-0.35; 0.31]			- 10		
Total (95% CI)		146			142	53.6%	-0.12 [-0.35; 0.11]		-	-		
Heterogeneity: $Tau^2 = 0$; Chi ² = 0.69, df =	3 (P = 0	.88); I ²	= 0% P=0 .	672		-					
Total (95% CI)	01 ² 0.00 1	269	201 12		268	100.0%	-0.09 [-0.25; 0.08]	_		-		_
Heterogeneity: Tau" = 0	$Cni = 2.00, df = 0.00^{2}$	6 (P = 0	.92); 1	= 0%	C	verall effe	ct: P=0.325	4	0.5		0.5	
lest for subgroup differ	ences: Chr = 0.1	, aī = 1	(P = 0.6)	8)				-1	-0.5	0	0.5	1
									Exp		CNT	

Figure 6. The forest plot shows the effect of various treatments (Exp) on fasting blood glucose (FBG) levels compared with the comparator control (CNT) in patients with NAFLD.

															Fig	. 7	
HOMA-IR																	
Study Chan 2017 Rajendra 2022 Abenavoli 2015	Exper Mean 0.50 -0.19 -2.36	9.560 0.810 2.280	al D Tota 0 49 0 29 0 10	Mea 0.6 0 -0.1	Col in 50 5.2 1 0.6 26 2.8	ntrol SD T 2100 5500 3700	otal V 50 30 10	Neight 30.0% 25.0% 12.6%	Std. IV, -0 -0	Mean Rando .01 [-0. .11 [-0. .97 [-1.	Difference m, 95% (41; 0.38 62; 0.40 91; -0.03	ce CI]] -	S	td. Mea V, Rand	n Diff om, 9	erence 5% CI	
rang 2020	-0.99	1.730	10 70	0.	0 1./	700	70	32.4%	-0.	.0-] co.	99;-0.31	1		-			
Total (95% CI) Heterogeneity: Tai	u ² = 0.09	964; CI	158 hi ² = 8.3	3 9, df =	3 (P =	0.04);	160 1 1 ² = 64%	00.0% ^{&} Ove	-0. rall	36 [-1. effect	02; 0.29) :: P=0.17] 74	-1.5	-1 -0.5	0 0	.5 1	⊐ 1.5
BMI														Ехр		CNI	
A) Other thera	pies																
Study or Subgroup	Ex M	iperim ean	ental SD 1	fotal I	Mean	Contro SE	l) Tota	l Weig	S ^t ht	td. Mea IV, Fix	n Differe ed, 95% (nce Cl		Std. Me IV, Fib	an Di œd, 9	fference 5% Cl	e
subgroup = sub	group1		5000	50	0.00	0.5700			~	0.071		71			i L		
Abenavoli 2009	-0	115 2	1000	10	-0.38	3.5700	50	24.5	%	-] 10.0	0.32; 0.4	201					
Chiurazzi 2022	-2	70 8	5000	36	-2 10	6 2000) 32	16.6	%	-0.08	-0.56: 0.4	101				_	
Liu 2012	-1	.52 1	6100	42	-0.26	1.4900) 34	17.0	%	-1 08.0-	1.27:-0.3	331	-				
Total (95% CI)				138			126	63.0	%	-0.21 [-	0.46; 0.0)3j		-	-		
Heterogeneity: Tau	² = 0.11	65; Chi	² = 8.43,	df = 3	(P = 0	0.04); I ² :	= 64%	P=0.3	343			-			11		
B) Silymarin + subgroup = subgroup = subg	- Lifes group2	tyle r	nodifi	catio	n												
Anushiravani 20	19 -0	0.80 3	.3000	30	-0.70	2.8800) 30	14.7	%	-0.03 [-	0.54; 0.4	[7]					
Famouri 2017	C	0.00 4	1000	20	0.90	4.1900	20	9.7	%	-0.21 [·	-0.83; 0.4	[1]			•		
Mirhashemi 202	2 -1	.22 4	.5100	27	-0.10	3.8000) 25	12.6	%	-0.26 [-0.81; 0.2	28]				_	
Iotal (95% CI)	2 0.0	2 0		11	0.041	2 001	75	37.0	%	-0.16 [-	0.48; 0.1	6]					
Heterogeneity: Tau	1 = 0; C	ni = 0,4	41, OT = 7	2 (P =	0.81);	1 = 0%	P=0.	331									
Total (95% CI) Heterogeneity: Tau	$u^2 = 0.04$	25: Chi	² = 8.92	215 df = 6	(P = 0	(18): 1 ²	201 = 33%	100.0	%	-0.19 [-	0.39; 0.0	00]	Г		-		_
Test for subgroup of	differenc	es: Chi	² = 0.08	df = 1	(P = 0	0.78)	(Overal	l eff	ect: P	<0.05		-1	-0.5 Exp	0	0.5 CNT	1

Figure 7. The forest plot shows the effect of various treatments (Exp) on the homeostatic model assessment of insulin resistance (HOMA-IR) and body mass index (BMI) compared with the comparator control (CNT) in patients with NAFLD.

ALT

A) Silymarin Fig. 8 Std. Mean Difference Experimental Control Std. Mean Difference IV, Random, 95% CI Study Mean SD Total Mean SD Total Weight IV, Random, 95% CI Ataee 2021 -12.19 32.4000 24 -7.35 25.5400 19.0% -0.16 [-0.72; 0.39] 26 Chan 2017 0.02 [-0.37; 0.42] -20.00 50.5800 49 -21.00 42.4200 50 20.4% Rajendra 2022 -1.21 6.3100 -0.69 [-1.21; -0.16] 29 3.63 7.5100 30 19.3% Shaikh 2021 -22.40 6.3400 100 -9.60 7.6400 100 20.9% -1.82 [-2.15; -1.49] Hashemi 2009 -40.40 57.5500 50 -14.62 41.8300 50 20.4% -0.51 [-0.91; -0.11] 256 100.0% Total (95% CI) 252 -0.64 [-1.55; 0.26] Heterogeneity: Tau² = 0.4960; Chi² = 60.31, df = 4 (P < 0.01); l² = 93% P=0.120 -2 0 2 -1 1 CNT Exp

B) Silymarin + Lifestyle modification

	Expe	rimental			Control			Std. Mean Difference	•	Std. Me	an Di	fference	
Study	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% CI		IV, Fit	xed, 9	5% CI	
Anushiravani 2019	-9.30	15.9100	30	-0.60	14.6000	30	17.6%	-0.56 [-1.08; -0.05]			-		
Curcio 2020	-44.46	19.5000	41	-16.11	36.4000	40	22.0%	-0.97 [-1.43; -0.50]		_			
Mirhashemi 2022	-5.05	17.7200	27	3.84	10.9900	25	15.1%	-0.59 [-1.15; -0.03]			_		
Solhi 2014	-52.90	18.4800	33	-32.30	27.2100	31	17.7%	-0.88 [-1.39; -0.37]		-			
Chen 2012	-14.96	3.0600	30	-10.75	2.5800	30	14.2%	-1.47 [-2.04; -0.89]	-	-			
Li 2010	-84.38	33.1400	30	-56.01	33.4100	20	13.4%	-0.84 [-1.43; -0.25]		-	-		
Total (95% CI)		. 2	191		2	176	100.0%	-0.88 [-1.09; -0.66]	_	+			
Heterogeneity: Tau ⁺ = (0.0201; C	hr = 6.68,	df = 5	(P = 0.25)	$(5); 1^2 = 25\%$	5		D .0 0004					
								P<0.0001	-2	Exp	0	CNT	2

C) Silymarin + medication

	Expe	rimental			Control			Std. Mean Difference		Std.	Mean	n Di	ffere	nce	8
Study	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI		IV, F	land	om,	95%	CI	
Cui 2020	-38.76	8.4700	44	-24.62	9.2500	44	11.1%	-1.58 [-2.06; -1.10]			- 1				
Li 2018	-40.62	9.3500	48	-21.78	10.5400	48	11.1%	-1.88 [-2.36; -1.39]		-					
Lisheng 2018	-81.90	20.1400	50	-52.60	21.3000	48	11.1%	-1.40 [-1.85; -0.96]		-	-				
Liu 2012	-87.40	29.6600	42	-77.30	28.9500	34	11.1%	-0.34 [-0.80; 0.11]			+	-			
Wang 2013	-82.00	32.9200	65	-56.00	38.9700	65	11.2%	-0.72 [-1.07; -0.36]			-				
Xiao 2019	-32.80	11.1100	150	-67.20	9.9600	150	11.2%	3.25 [2.91; 3.60]			1				-
Yang 2020	-15.78	5.4900	70	-5.37	5.5400	70	11.1%	-1.88 [-2.28; -1.48]		-	-				
Zhang2018	-27.20	13.7700	50	-15.60	14.6700	50	11.1%	-0.81 [-1.22; -0.40]			-				
Zhao 2008	-89.40	34.5100	50	-58.20	30.5600	34	11.1%	-0.94 [-1.40; -0.48]		2	-				
Total (95% CI) Heterogeneity: T	au ² = 2.4	581: Chi ² :	569	9. df = 8	(P < 0.01)	543	100.0%	-0.69 [-1.91; 0.52]	_	-	-	+	1	-	-
				-,	(,			P=0.223	-3	-2 Exp	-1 0	0		2 T	3
Total (95% CI) Heterogeneity: Ta	au ² = 1.1	752: Chi ² =	1 652.06	012 5. df = 19	(P < 0.01)	9 1 ² = 97	75 100.0 %	% -0.73 [-1.25; -0.22]			+	-		-	٦
Test for subgroup	differen	ces: Chi ² =	0.53, d	f=2(P=	= 0.77)		Overa	Il effect: P=0.008	-3	-2	-1	0	1	2	3
J 1				,						Ex	p		CN	Т	

Figure 8. The forest plot shows the effect of various treatments (Exp) on alanine-aminotransferase (ALT) levels compared with the comparator control (CNT) in patients with NAFLD.

AST

A) Silymarin Experimental Control Std. Mean Difference Std. Mean Difference Study Mean SD Total Mean SD Total Weight IV, Random, 95% CI IV, Random, 95% CI Ataee 2021 24 -3.56 13.6900 -5.75 15.2300 26 19.7% -0.15 [-0.70; 0.41] -0.21 [-0.61; 0.18] -0.61 [-1.14; -0.09] Chan 2017 -13.00 37.8100 49 -6.00 25.9800 50 20.2% Rajendra 2022 -1.21 7.2800 29 3.17 6.8200 30 19.8% -3.10 [-3.52; -2.69] Shaikh 2021 -18.40 5.8000 100 -0.40 5.7600 100 20.1% Hashemi 2009 -21.76 57.5900 50 -6.86 35.1500 -0.31 [-0.70; 0.08] 50 20.2% 256 100.0% Total (95% CI) 252 -0.88 [-2.45; 0.68] Heterogeneity: Tau² = 1.5387; Chi² = 137.05, df = 4 (P < 0.01); I^2 = 97% P=0.193 -3 -2 -1

B) Silymarin + Lifestyle modification

Experimenta Study Mean SD Anushiravani 2019 -8.40 7.8800 Curcio 2020 -42.00 20.7300 Mirhashemi 2022 -5.59 16.2600 Solhi 2014 -32.30 9.5600 Chen 2012 -16.37 2.9100 Li 2010 -62.57 41.4900	$\begin{array}{c c c c c c c c c c c c c c c c c c c $	Std. Mean Difference tal Weight IV, Random, 95% CI 30 16.8% -0.75 [-1.28; -0.23] 40 17.3% -0.98 [-1.44; -0.52] 25 16.6% -0.29 [-0.84; 0.25] 31 17.1% 0.14 [-0.35; 0.63] 30 15.8% -2.02 [-2.65; -1.39] 20 16.4% -0.48 [-1.05; 0.10] 76 100.0% -0.72 [-1.49; 0.05]	Std. Mean Difference IV, Random, 95% CI
C) Silvmarin + Medication			Exp CNT
Experimental	Control	Std. Mean Difference	Std. Mean Difference
Study Mean SD To	al Mean SD Total	Weight IV, Random, 95% Cl	IV. Random, 95% CI
Cui 2020 -41.84 8.0700	44 -28.98 8.0500 44	12.3% -1.58 [-2.06: -1.10]	
Li 2018 -42.04 10.8600	48 -24.55 10.2500 48	12.4% -1.64 [-2.11; -1.18]	
Lisheng 2018 -40.70 10.8100	50 -20.70 11.2300 48	12.3% -1.80 [-2.27: -1.33]	
Wang 2013 -62.00 41.5800	5 -39.00 47.3200 65	12.7% -0.51 [-0.86: -0.16]	
Xiao 2019 -63.70 8.4900 1	50 -32.80 9,2000 150	12.7% -3.48 [-3.84: -3.12]	
Yang 2020 -11.29 9.4200	70 -4.47 9.6700 70	12.7% -0.71 [-1.05: -0.37]	-
Zhang2018 -14.90 9.8100	50 -4.50 10.0100 50	12.5% -1.04 [-1.46; -0.62]	
Zhao 2008 -66.40 10.5800	50 -53.80 35.9800 34	12.4% -0.51 [-0.96; -0.07]	
Total (95% CI) 5	27 509	100.0% -1.41 [-2.24; -0.59]	
Heterogeneity: Tau" = 0.9387; Chi" = 19	1.12, df = 7 ($P < 0.01$); $I^{-} = 96$	5% D=0.005	
		P=0.005	-3 -2 -1 0 1 2 3
			EXP CNT
Total (95% CI) Heterogeneity: Tau ² = 0.9375; Chi ² = 394	970 9 .82, df = 18 (P < 0.01); l ² = 95	41 100.0% -1.06 [-1.54; -0.58] %	· . +
Test for subgroup differences: Chi ² = 2.30	, df = 2 (P = 0.32)	Overall effect: P=0.0002	-3 -2 -1 0 1 2 3 Exp CNT

Figure 9. The forest plot shows the effect of various treatments (Exp) on aspartate-aminotransferase (AST) levels compared with the comparator control (CNT) in patients with NAFLD.

Fig. 9

CNT

1 2

> 3 2

> > ٦

2 3

CNT

Exp

0 1 2 3

Exp



Figure 10. The forest plot shows the effect of various treatments (Exp) on fatty liver score and hepatic steatosis rate compared with the comparator control (CNT) in patients with NAFLD.

•	Evnorin	antal	0	ontrol		Rick Ratio		Fig. 11
A)	Eugette	Tatal	Evente	Tatal	Mainht	IV Eined 0E% C		
AEs	Events 35	549	Events 16	513	40.9%	1.98 [1.11; 3.54]	IV, Fixed, 95% CI
B)						178 33 4	3	14 52
Gastrointestinal	10	549	5	513	12.1%	1.85 [0.64; 5.39	1	
Respiratory	5	549	2	513	5.1%	2.32 0.45; 11.93	ŝį	
Musculoskeletal	4	549	7	513	9.2%	0.54 [0.16; 1.82	Í	
Headache	5	549	3	513	6.8%	1.55 0.37; 6.46	í –	
Cardiac	4	549	2	513	4.8%	1.86 [0.34; 10.13	<u>ŝ</u> j	· · · · · · · · · · · · · · · · · · ·
Other	21	549	8	513	21.2%	2.40 [1.07; 5.37	1	
Total (95% CI)		3843		3591	100.0%	1.80 [1.24; 2.60	1	-
Heterogeneity: Tai	u ² = 0; Chi	$^{2} = 4.4$	9. df = 6 (P = 0.6	1); $I^2 = 0\%$	6		
	151 - FOÂK(SE)					P=0.002	0.1	0.5 1 2 10
								CNI Exp

Figure 11. The forest plot shows (A) the proportion of patients with adverse effects (AEs) and (B) the proportion of AEs incidence in patients with NAFLD. Exp: silymarin group; CNT: the comparator control.